MyoKardia appoints two to board
Ms. Popovits has served as Genomic Health’s chairman of the board since 2012, and chief executive officer and president since 2009.
She was president and chief operating officer since joining the company in 2002.
Previously, Ms. Popovits spent 15 years at Genentech, where she led the successful commercialization of 14 new therapies.
Ms. Yarno, retired chief marketing officer of Merck & Co, Inc., is an accomplished global business leader recognized for expertise in marketing and organizational effectiveness.
During her 26 years at Merck, Ms. Yarno held positions of increasing responsibility and developed deep expertise in pharmaceutical commercialization including drug development, regulatory strategy, market development, global product strategy and management of product lifecycles.
Ms. Yarno also served as Merck’s senior vice president of human resources, where her efforts to develop and implement new corporate HR strategies proved transformative.
Ms. Yarno has more than 14 years of corporate governance experience as a member of public company boards in the medical device and biotechnology fields.
She is the non-executive chairman of the board of Aratana Therapeutics and has served on the boards of ADial Pharmaceuticals, Durata Therapeutics, Medivation, St. Jude Medical, and PluroGen Therapeutics. Ms. Yarno holds an M.B.A. from Temple University.
Ms. Yarno will serve on the compensation committee of MyoKardia’s board of directors. ■
LATEST MOVES FROM California
- Reed's appoints Stefan Freeman as interim CEO
- Heron Therapeutics appoints Robert E. Hoffman as CFO
- Penumbra appoints Bridget O'Rourke to board
- Adverum Biotechnologies adds Richard N. Spivey to board
- Lombard Medical appoints Kurt Lemvigh as CEO
More inside POST